# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite hol...
Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $135 to $...
Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and raises the price target from $133 to $150.
DaVita (NYSE:DVA) reported quarterly Adj earnings of $2.38 per share which beat the analyst consensus estimate of $1.95 by 22.0...
Efforts to advance chronic disease prevention through enhanced education, awareness and support — kicking off during National K...